Compare Biogen Inc (BIIB) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $20.69. The key difference: Biogen Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | BOIL | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $87.24 |
52-Week Low | $128.93 | $18.74 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
BOIL trades at $20.91, up 0.97% with a bearish technical signal as moving averages indicate selling pressure. The stock recently underwent a 1:2 split effective May 28, 2026. Natural gas market volatility and weather-driven demand fluctuations create trading opportunities, though financial fundamentals remain undisclosed in current data.
Outlook hinges on natural gas price movements and energy sector dynamics. Investment appeal lies in leveraged exposure to gas futures via the ETF structure, but risks include commodity price swings and lack of traditional corporate fundamentals. Bearish technicals suggest cautious entry points near support at $20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
